发布求助
文献互助 智能选刊 最新文献

Medical Letter on Drugs and Therapeutics最新文献

筛选
英文 中文
Drugs for gout. 治疗痛风的药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-30 DOI: 10.58347/tml.2023.1688a
{"title":"Drugs for gout.","authors":"","doi":"10.58347/tml.2023.1688a","DOIUrl":"10.58347/tml.2023.1688a","url":null,"abstract":"Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AD-Detect - A blood test for Alzheimer's disease. AD检测-阿尔茨海默病的血液检测。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-30 DOI: 10.58347/tml.2023.1688b
{"title":"AD-Detect - A blood test for Alzheimer's disease.","authors":"","doi":"10.58347/tml.2023.1688b","DOIUrl":"10.58347/tml.2023.1688b","url":null,"abstract":"AD-Detect (Quest), a blood test to evaluate Alzheimer's disease risk, is being marketed directly to consumers. It has not been cleared or approved by the FDA (laboratory-developed tests like this one currently do not need FDA authorization to be marketed).","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison table: Some drugs for gout. 对照表：一些治疗痛风的药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-30 DOI: 10.58347/tml.2023.1688c
{"title":"Comparison table: Some drugs for gout.","authors":"","doi":"10.58347/tml.2023.1688c","DOIUrl":"10.58347/tml.2023.1688c","url":null,"abstract":"Comparison Table of some drugs for gout","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza vaccine for 2023-2024. 2023-2024年流感疫苗。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-16 DOI: 10.58347/tml.2023.1687a
{"title":"Influenza vaccine for 2023-2024.","authors":"","doi":"10.58347/tml.2023.1687a","DOIUrl":"10.58347/tml.2023.1687a","url":null,"abstract":"Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1,2 Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 update: New Pfizer and Moderna vaccine formulations for 2023-2024. 新冠肺炎更新：2023-2024年辉瑞和莫德纳新疫苗配方。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-16 DOI: 10.58347/tml.2023.1687c
{"title":"COVID-19 update: New Pfizer and Moderna vaccine formulations for 2023-2024.","authors":"","doi":"10.58347/tml.2023.1687c","DOIUrl":"10.58347/tml.2023.1687c","url":null,"abstract":"New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) that more closely target currently circulating variants have been licensed by the FDA for use in persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old. The bivalent (original and Omicron BA.4/5) formulations of the Pfizer and Moderna vaccines are no longer authorized for use in the US.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nalmefene nasal spray (Opvee) for reversal of opioid overdose. Nalmefene鼻喷雾剂（Opvee）用于逆转阿片类药物过量。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-16 DOI: 10.58347/tml.2023.1687b
{"title":"Nalmefene nasal spray (Opvee) for reversal of opioid overdose.","authors":"","doi":"10.58347/tml.2023.1687b","DOIUrl":"10.58347/tml.2023.1687b","url":null,"abstract":"The FDA has approved an intranasal formulation of the opioid antagonist nalmefene (Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene, which is available by prescription, is the second opioid antagonist to become available as a nasal spray for this indication; the first was naloxone, which is now available for sale over the counter (Narcan, and generic).","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quizartinib (Vanflyta) for acute myeloid leukemia. 喹唑替尼治疗急性粒细胞白血病。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-16 DOI: 10.58347/tml.2023.1687d
{"title":"Quizartinib (Vanflyta) for acute myeloid leukemia.","authors":"","doi":"10.58347/tml.2023.1687d","DOIUrl":"10.58347/tml.2023.1687d","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccination recommendations for updated 2023-2024 COVID-19 vaccines. 更新的2023-2024年新冠肺炎疫苗接种建议。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-16 DOI: 10.58347/tml.2023.1687e
{"title":"Vaccination recommendations for updated 2023-2024 COVID-19 vaccines.","authors":"","doi":"10.58347/tml.2023.1687e","DOIUrl":"10.58347/tml.2023.1687e","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy. Delandistrogene moxeparvovec（Elevidys）治疗Duchenne肌营养不良。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-02 DOI: 10.58347/tml.2023.1686d
{"title":"Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy.","authors":"","doi":"10.58347/tml.2023.1686d","DOIUrl":"10.58347/tml.2023.1686d","url":null,"abstract":"Delandistrogene moxeparvovec-rokl (Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. It is the first gene therapy to be approved in the US for treatment of DMD. Accelerated approval was based on expression of microdystrophin in skeletal muscle, a surrogate endpoint.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41175280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addendum: Gabapentinoids and renal impairment. 附录：加巴喷丁类药物与肾损伤。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-02 DOI: 10.58347/tml.2023.1686e
{"title":"Addendum: Gabapentinoids and renal impairment.","authors":"","doi":"10.58347/tml.2023.1686e","DOIUrl":"https://doi.org/10.58347/tml.2023.1686e","url":null,"abstract":"A nephrologist and longtime reader of The Medical Letter wrote us to say that our recent article entitled Drugs for Anxiety Disorders should have said more about the need for dosage adjustment of gabapentin (Neurontin, and others) and pregabalin (Lyrica, and others) in patients with renal impairment.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41142087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信